Aethlon Medical, Inc. — FY2013 Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2013; comparisons are with the fiscal year ended March 31, 2012. The filing was signed July 15, 2013. Although the request refers to 2012 Q4, this is an annual report covering FY2013, not a standalone quarterly filing.
Business context and development
Aethlon is a medical-device company developing its ADAPT platform, including the Hemopurifier for infectious disease and cancer applications and a DARPA-funded device intended to reduce sepsis risk. Revenue remained principally milestone payments under the DARPA contract; the company reported no product sales in FY2013.
After year-end, the FDA approved an Investigational Device Exemption on June 25, 2013 for a U.S. feasibility study involving 10 HCV-infected patients with end-stage renal disease. The company expected the study to begin later in 2013 and finish in the first half of 2014. This approval permits a feasibility study, not commercial marketing or proof of efficacy.
Financial performance and liquidity
| Metric | FY ended Mar. 31, 2013 | FY ended Mar. 31, 2012 |
|---|---|---|
| Total revenue | $1,230,004 | $1,359,621 |
| Operating expenses | $4,805,358 | $4,473,956 |
| Operating loss | $(3,575,354) | $(3,114,335) |
| Net loss | $(4,892,040) | $(8,111,340) |
| Basic and diluted loss per share | $(0.03) | $(0.08) |
| Cash from operating activities | $(2,098,857) | $(1,841,355) |
| Cash from financing activities | $2,080,224 | $1,971,293 |
- FY2013 revenue was $1,230,004 from DARPA milestones, down from $1,358,189 of contract revenue in FY2012; FY2012 also included $1,432 in product sales.
- Operating expenses increased 7.4%, primarily reflecting higher professional fees and a full year of payroll for scientists hired for the DARPA project. Operating loss widened despite lower revenue.
- Net loss improved by about $3.22 million, mainly because FY2012 had substantially higher interest and other debt charges, debt-discount amortization, and derivative fair-value expense. This improvement did not reflect operating profitability.
- No gross profit or gross margin is clearly reported. The company had no commercial product sales in FY2013.
- At March 31, 2013, cash was $125,274, working capital deficit was $9,276,618, total assets were $496,694, and current liabilities were $9,641,138. Accumulated deficit was $61,475,325.
- Cash used in operations increased to $2.10 million. Financing provided $2.08 million, principally from common-stock issuance; cash declined by $18,633 during the year.
- Balance-sheet debt included $321,381 of notes payable and $2,367,631 of convertible notes payable net of discounts. The filing also identifies $2,261,916 of overdue promissory notes in its risk discussion; many obligations were past due or in default. Derivative liabilities were $3,588,239.
Material changes and financing
- DARPA exercised the contract’s second-year option in August 2012. Years three through five remain optional, and DARPA may cancel the contract. The five-year contract has potential payments of approximately $6.79 million, subject to milestones and contract terms.
- Aethlon issued 29.7 million shares for cash and 21.9 million shares upon debt conversions during FY2013. It also issued shares for services and license fees. Shares outstanding rose from 117.5 million at March 31, 2012 to 173.7 million at March 31, 2013; 182.6 million were reported outstanding July 11, 2013.
- At March 31, 2013, options, warrants, and convertible notes represented approximately 142.7 million potential additional shares, subject to their terms. The filing warns of substantial potential dilution.
- After year-end through July 11, 2013, the company reported $128,000 from private equity transactions, $400,000 in loans from two directors, and $404,362 collected under DARPA. Management nevertheless stated that these resources were not sufficient for the next 12 months.
Outlook, risks, contingencies, and controls
- Management expects continuing losses and negative cash flows and says operations depend for at least several years on raising equity or debt, or securing other funding. The auditor’s report and management disclosures state that substantial doubt exists about the company’s ability to continue as a going concern.
- Management said additional capital is needed to fund operations and the U.S. clinical study. It identified potential revenue sources including future government awards, a Battelle subcontract, collaborations, diagnostic products, and possible Hemopurifier activity in India; these are prospective and not assured. Expected Battelle subcontract revenue was at Battelle’s discretion.
- Clinical development, regulatory approval, manufacturing scale-up, market acceptance, intellectual-property protection, and limited staffing are material risks. Prior clinical observations cited by the company are not a substitute for controlled U.S. efficacy evidence.
- The company is defending a lawsuit brought by Gemini Master Fund alleging note default and failures to issue shares. The case was in late discovery with no trial date set; an adverse outcome could affect operations and dilute shareholders.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at March 31, 2013 due to material weaknesses involving segregation of duties, cash disbursements, and insufficient accounting personnel. Audit adjustments and disclosure revisions resulted; remediation was planned.
- The company reported no material unusual or infrequently occurring fourth-quarter adjustments for FY2013. No formal commercial revenue or profitability guidance was provided.
Important facts for investors to verify
- Current cash runway, funding needs, and the status and terms of subsequent equity and director-loan financing.
- Status, payment, and restructuring of overdue debt, accrued interest, and the Gemini litigation; confirm which obligations remain in default.
- Progress and costs of the FDA-authorized 10-patient feasibility study, including enrollment, safety findings, and whether later pivotal trials are funded.
- Whether DARPA exercises future contract options and the amount and timing of any Battelle subcontract work.
- Fully diluted share count and the impact of outstanding warrants, options, convertible debt, and any additional financing.
- Progress in remediating the disclosed material weaknesses and whether subsequent filings report effective controls.